These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 25120005)

  • 1. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes.
    Jullien D; Prinz JC; Nestle FO
    J Invest Dermatol; 2015 Jan; 135(1):31-38. PubMed ID: 25120005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
    Bito T; Nishikawa R; Hatakeyama M; Kikusawa A; Kanki H; Nagai H; Sarayama Y; Ikeda T; Yoshizaki H; Seto H; Adachi A; Horikawa T; Oka M; Nishigori C
    Br J Dermatol; 2014 Apr; 170(4):922-9. PubMed ID: 24329764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.
    Zhu Y; Marini JC; Song M; Randazzo B; Shen YK; Li S; Zhou H
    J Invest Dermatol; 2019 Aug; 139(8):1830-1834.e6. PubMed ID: 30851300
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.
    Carrascosa JM; van Doorn MB; Lahfa M; Nestle FO; Jullien D; Prinz JC
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1424-30. PubMed ID: 24841895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection.
    Heron CE; Ghamrawi RI; Balogh EA; Feldman SR
    Am J Clin Dermatol; 2021 Mar; 22(2):221-231. PubMed ID: 33169802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.
    Gunn GR; Sealey DC; Jamali F; Meibohm B; Ghosh S; Shankar G
    Clin Exp Immunol; 2016 May; 184(2):137-46. PubMed ID: 26597698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.
    Kimball AB; Kerbusch T; van Aarle F; Kulkarni P; Li Q; Blauvelt A; Papp KA; Reich K; Montgomery D
    Br J Dermatol; 2020 Jan; 182(1):180-189. PubMed ID: 30916381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis].
    Jullien D
    Ann Dermatol Venereol; 2012 Apr; 139 Suppl 2():S58-67. PubMed ID: 22541730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?
    De Simone C; Amerio P; Amoruso G; Bardazzi F; Campanati A; Conti A; Gisondi P; Gualdi G; Guarneri C; Leoni L; Loconsole F; Mazzotta A; Musumeci ML; Piaserico S; Potenza C; Prestinari F
    Expert Opin Biol Ther; 2013 Dec; 13(12):1673-82. PubMed ID: 24107126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?].
    Goupille P
    Rev Med Interne; 2016 May; 37(5):343-9. PubMed ID: 26526777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils.
    Yamanaka K; Umezawa Y; Yamagiwa A; Saeki H; Kondo M; Gabazza EC; Nakagawa H; Mizutani H
    J Dermatol; 2014 Aug; 41(8):679-85. PubMed ID: 25099154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viewpoint on handling anti-TNF failure in psoriasis.
    Bracke S; Lambert J
    Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of biologics used in the treatment of moderate to severe psoriasis.
    Patel V; Efimov A; Baker D; Kang AS
    Hum Antibodies; 2021; 29(3):171-178. PubMed ID: 34151782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of ustekinumab in psoriasis.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Mar; 12(3):317-20. PubMed ID: 23545915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
    Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
    BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting response to biologic treatment in psoriasis.
    Karczewski J; Poniedziałek B; Rzymski P; Adamski Z
    Dermatol Ther; 2014; 27(6):323-30. PubMed ID: 25053228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.